

ALDER BIOPHARMACEUTICALS INC
Form 10-Q
August 05, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 001-36431

Alder BioPharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction)

90-0134860
(I.R.S. Employer

of incorporation or organization) Identification No.)

11804 North Creek Parkway South

Bothell, WA 98011

(Address of principal executive offices including zip code)

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 10-Q

Registrant's telephone number, including area code: (425) 205-2900

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒ (do not check if a smaller reporting company) Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of July 31, 2015 the registrant had 43,510,641 shares of common stock, \$0.0001 par value per share, outstanding.

Alder BioPharmaceuticals, Inc.

Quarterly Report on Form 10-Q

For the Quarter Ended June 30, 2015

INDEX

Page

PART I. FINANCIAL INFORMATION (Unaudited)

Item 1.	<u>Condensed Consolidated Financial Statements</u>	3
	<u>Condensed Consolidated Balance Sheets</u>	3
	<u>Condensed Consolidated Statements of Operations</u>	4
	<u>Condensed Consolidated Statements of Comprehensive Loss</u>	5
	<u>Condensed Consolidated Statements of Cash Flows</u>	6
	<u>Notes to Condensed Consolidated Financial Statements</u>	7
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	12
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	19
Item 4.	<u>Controls and Procedures</u>	20

PART II. OTHER INFORMATION

Item 1.	<u>Legal Proceedings</u>	21
		21

Item 1A. Risk Factors

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46

Item 6. Exhibits 47

SIGNATURES 48

In this Quarterly Report on Form 10-Q, “we,” “our,” “us,” “Alder,” and “the Company” refer to Alder BioPharmaceuticals, Inc. and, where appropriate, its consolidated subsidiaries. “Alder” and the Alder logo are the property of Alder BioPharmaceuticals, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies

.

2

PART I. – FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Alder BioPharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

	June 30, 2015	December 31, 2014
	(in thousands, except share and per share data)	
Assets		
Current assets		
Cash and cash equivalents	\$407,966	\$46,795
Short-term investments	20,447	9,077
Accounts receivable	—	113
Prepaid expenses and other assets	13,652	4,758
Total current assets	442,065	60,743
Other assets	12	2,456
Property and equipment, net	1,419	1,160
Total assets	\$443,496	\$64,359
Liabilities and stockholders' equity		
Current liabilities		
Accounts payable	\$2,354	\$1,911
Accrued liabilities	4,211	2,963
Deferred rent	149	135
Total current liabilities	6,714	5,009
Deferred rent	112	193
Total liabilities	6,826	5,202
Commitments and contingencies		
Stockholders' equity		
Common stock; \$0.0001 par value; 200,000,000 shares authorized;		
43,502,186 and 30,996,526 shares issued and outstanding, respectively	4	3
Additional paid-in capital	605,920	196,082
Accumulated deficit	(169,214)	(136,906)
Accumulated other comprehensive loss	(40)	(22)
Total stockholders' equity	436,670	59,157
Total liabilities and stockholders' equity	\$443,496	\$64,359

The accompanying notes are an integral part of these condensed consolidated financial statements.

Alder BioPharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2015	2014	2015	2014
	(in thousands, except share and per share data)			
Revenues				
Collaboration and license agreements	\$—	\$4,703	\$—	\$9,485
Operating expenses				
Research and development	14,088	9,377	25,123	16,397
General and administrative	3,930	2,736	7,607	5,896
Total operating expenses	18,018	12,113	32,730	22,293
Loss from operations	(18,018)	(7,410)	(32,730)	(12,808)
Other income				
Interest income	74	9	133	12
Foreign currency gain	289	—	289	—
Total other income	363	9	422	12
Net loss	\$(17,655)	\$(7,401)	\$(32,308)	\$(12,796)
Net loss per share - basic and diluted	\$(0.46)	\$(0.40)	\$(0.86)	\$(1.30)
Weighted average number of common shares used in net loss				
per share - basic and diluted	38,162,226	18,556,561	37,536,331	9,827,883

The accompanying notes are an integral part of these condensed consolidated financial statements.

Alder BioPharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(unaudited)

Three Months		Six Months	
Ended		Ended	
June 30,		June 30,	
2015	2014	2015	2014
(in thousands)		(in thousands)	